Use of antibiotics in bronchiectasis

Reviews on Recent Clinical Trials

Volumn 7, Issue 1, 2012, Pages 24-30

  King, Paul T ^a,b   Holmes, Peter W ^a  

^a MONASH MEDICAL CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Antibiotic Resistance; Bronchiectasis; Inhalational; Lung; Macrolide

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTAZIDIME; CIPROFLOXACIN; CLARITHROMYCIN; COLISTIN; ERYTHROMYCIN; FOSFOMYCIN; GENTAMICIN; MACROLIDE; OFLOXACIN; QUINOLONE DERIVATIVE; ROXITHROMYCIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BRONCHIECTASIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; TREATMENT RESPONSE;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; HUMANS; TIME FACTORS;

EID: 84857422474     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/157488712799363280     Document Type: Review

References (45)

1. Barker AF: Bronchiectasis. N Engl J Med 2002, 346: 1383-1393.
2. King P, Holdsworth S, Freezer N, Holmes P: Bronchiectasis. Intern Med J 2006, 36: 729-737.
3. McGuinness G, Naidich DP: CT of airways disease and bronchiectasis. Radiol Clin North Am 2002, 40: 1-19.
4. Patel IS, Vlahos I, Wilkinson TM, et al. Bronchiectasis, Exacerbation Indices and Inflammation in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2004.
5. King PT, Holdsworth SR, Farmer M, et al. Phenotypes of adult bronchiectasis: onset of productive cough in childhood and adulthood. COPD 2009, 6: 130-136.
6. King PT, Holdsworth SR, Freezer NJ, et al. Outcome in Adult Bronchiectasis. Journal of Chronic Obstructive Pulmonary Disease 2005, 2: 27-34.
7. King PT, Holdsworth SR, Freezer NJ, et al. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med 2006, 100: 2183-2189.
8. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007, 132: 1565-1572.
9. King PT, Holdsworth SR, Freezer NJ, et al. Microbiologic followup study in adult bronchiectasis. Respir Med 2007, 101: 1633-1638.
10. Fowler SJ, French J, Screaton NJ, et al. Nontuberculous mycobacteria in bronchiectasis: Prevalence and patient characteristics. Eur Respir J 2006, 28: 1204-1210.
11. Angrill J, Agusti C, de Celis R, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002, 57: 15-19.
12. Chang AB, Grimwood K, Maguire G, et al. Management of bronchiectasis and chronic suppurative lung disease in indigenous children and adults from rural and remote Australian communities. Med J Aust 2008, 189: 386-393.
13. Lam WK, Chau PY, So SY, et al. A double-blind randomized study comparing ofloxacin and amoxicillin in treating infective episodes in bronchiectasis. Infection 1986, 14 Suppl 4: S290-292.
14. Hill SL, Morrison HM, Burnett D, et al. Short term response of patients with bronchiectasis to treatment with amoxycillin given in standard or high doses orally or by inhalation. Thorax 1986, 41: 559-565.
15. Hill SL, Stockley RA: Effect of short and long term antibiotic response on lung function in bronchiectasis. Thorax 1986, 41: 798-800.
16. Lin HC, Cheng HF, Wang CH, et al. Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. Am J Respir Crit Care Med 1997, 155: 2024-2029.
17. Murray MP, Pentland JL, Hill AT: A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J 2009, 34: 1086-1092.
18. Evans DJ, Bara AI, Greenstone M: Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database Syst Rev 2007: CD001392.
19. Chang AB, Bilton D: Exacerbations in cystic fibrosis: 4--Noncystic fibrosis bronchiectasis. Thorax 2008, 63: 269-276.
20. Rayner CF, Tillotson G, Cole PJ, et al. Efficacy and safety of longterm ciprofloxacin in the management of severe bronchiectasis. J Antimicrob Chemother 1994, 34: 149-156.
21. Hansen CR, Pressler T, Hoiby N: Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008, 7: 523-530.
22. Rubin BK: Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv 2008, 21: 71-76.
23. Orriols R, Roig J, Ferrer J, et al. Inhaled antibiotic therapy in noncystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med 1999, 93: 476-480.
24. Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000, 162: 481-485.
25. Drobnic ME, Sune P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005, 39: 39-44.
26. Scheinberg P, Shore E: A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005, 127: 1420-1426.
27. Bilton D, Henig N, Morrissey B, et al. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006, 130: 1503-1510.
28. Steinfort DP, Steinfort C: Effect of long-term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis. Intern Med J 2007, 37: 495-498.
29. Dhar R, Anwar GA, Bourke SC, et al. Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa. Thorax 2010, 65: 553.
30. Murray MP, Govan JR, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. American journal of respiratory and critical care medicine 2011, 183: 491-499.
31. Bilton D, Bruinenberg P, Otulana B, et al. Inhaled liposomal hdrochloride significantly reduces sputum pseudomonas aeruginosa density in CF and non-CF bronchiectasis. In. Amercian Journal of Respiratory and Critical Care Medicine; 2009: A3214.
32. O' Donnell AE, Swarnaker R, Yahina L, et al. A placebo-controlled study of liposomal amikacin for inhalation nebulized once daily in the treatment of bronchiectasis patients with chronic Pseudomonas aeruginosa lung infection. In European Respiratory Journal vol. 34. pp. 231S; 2009: 231S.
33. MacLeod DL, Barker LM, Sutherland JL, et al. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 2009, 64: 829-836.
34. King P: Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis? Drugs 2007, 67: 965-974.
35. Koh YY, Lee MH, Sun YH, et al. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J 1997, 10: 994-999.
36. Tsang KW, Ho PI, Chan KN, et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999, 13: 361-364.
37. Davies G, Wilson R: Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax 2004, 59: 540-541.
38. Cymbala AA, Edmonds LC, Bauer MA, et al. The diseasemodifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med 2005, 4: 117-122.
39. Yalcin E, Kiper N, Ozcelik U, et al. Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther 2006, 31: 49-55.
40. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999, 340: 23-30.
41. LiPuma JJ: Microbiological and immunologic considerations with aerosolized drug delivery. Chest 2001, 120: 118S-123S.
42. Fowler SJ, French J, Screaton NJ, et al. Non-tuberculous mycobacteria in bronchiectasis: Prevalence and patient characteristics. Eur Respir J 2006.
43. Griffith DE, Brown-Elliott BA, Langsjoen B, et al. Clinical and Molecular Analysis of Macrolide Resistance in Mycobacterium avium Complex Lung Disease. Am J Respir Crit Care Med 2006, 174: 928-934.
44. Pasteur MC, Bilton D, Hill AT: British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010, 65 Suppl 1: i1-58.
45. Chang AB, Bell SC, Byrnes CA, Grimwood K, Holmes PW, King PT, Kolbe J, Landau LI, Maguire GP, McDonald MI, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. The Medical journal of Australia 2010, 193: 356-365.